Sklice, Topical Ivermectin 0.5% for Head Lice on Scalp and Hair

Written by on October 10, 2012 in Demodex Mites, Ivermectin, Rosacea Topicals with 2 Comments
sklice

A new prescription topical ivermectin product called Sklice is being promoted in the United States. Sanofi Pasteur received FDA approval for Sklice as a treatment for Head Lice in humans.

The interest for rosacea sufferers in topical ivermectin has been motivated by the large scale trials that Galderma is undertaking with CD5024. CD5024 is a code name for a possible future product that is known to contain topical ivermectin 1%.

What is Sklice?

Sklice is listed as “a prescription medication for topical use on the hair and scalp only, used to treat head lice in children 6 months of age and older”.

So Sklice is not FDA approved as a rosacea treatment.

Off Label Treatment

As Sklice is FDA approved for the treatment of Head Lice, a doctor is legally allowed to prescribe Sklice off-label for another condition. Thus with the support of your doctor, Sklice can be dispensed a rosacea treatment. Given the strict prescribing information supplied with Sklice, the support and close supervision of a doctor will be required for any rosacea experimentation.

It is unknown how the formulation of Sklice may differ to the proposed CD5024 other than Sklice contains 0.5% Ivermectin and CD5024 contains 1% Ivmermectin. The formulation may differ in ways that are important for rosacea sufferers – especially as Galderma are specifically targeting CD5024 to rosacea sufferers. This distinction is important because the all important safety information will be able to include real world rosacea sufferers.

Please do not take this post as medical advice that Sklice is suitable as a treatment for rosacea.

Known Side Effects

The sklice web site lists the following safety information.

  • To prevent accidental ingestion, adult supervision is required for pediatric application. Avoid contact with eyes.
  • The most common side effects from Sklice Lotion include eye redness or soreness, eye irritation, dandruff, dry skin, burning sensation of the skin.

Further;

  • Do not swallow Sklice Lotion. If swallowed, call your healthcare provider or go to the nearest emergency room right away.
  • Do not get Sklice Lotion into your eyes. If Sklice Lotion gets in your eye, gently flush with water.

Note that the safety trials of Sklice only considered a single application of Sklice applied for 10 minutes and then washed off.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

2 Reader Comments

  1. DaveM81 says:

    I just hope (a little premature I know!) that this won’t end up with overuse? As I understand it permethrin, the standard headlice treatment now has low efficacy against headlice – is this a result of overuse/resistance?

    It would be galling if such a potentially revolutionary treatment for papulopustular rosacea sufferers were to be affected in this way.

    I would guess that the reason this has made it to market quicker than ‘our’ product is contained in the last paragraph – this hasn’t been subjected to the more extensive trials needed for a daily use product.

  2. Patrick says:

    Careful, Ivermectin is a powerful compound. I would wait on the completion of Galderma’s safety studies since Sklice has a very short treatment cycle and studies would likely not have looked at side effects (if any) associated long-term use.

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.